Rodrigo Madurga

Dr. Rodrigo Madurga

Fundación de Investigación HM Hospitales
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 January 2022 in Nature
Verified
Journal Article
Closed access
PDF file
GCGeorgiana Crainiciuc
Georgiana Crainiciuc
MPMiguel Palomino-Segura
Miguel Palomino-Segura
MMMiguel Molina-Moreno
Miguel Molina-Moreno
JSJon Sicilia
Jon Sicilia
DADavid G. Aragones
David G. Aragones
AHAndrés Hidalgo
Andrés Hidalgo

11 March 2019 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
NGNoemi Garcia
Noemi Garcia
RMRodrigo Madurga
Rodrigo Madurga
GRGorjana Rackov
Gorjana Rackov
IAIrina Palacin Aliana
Irina Palacin Aliana
RNR. Núñez-Torres
R. Núñez-Torres
ÁAÁngel Ayuso-Sacido
Ángel Ayuso-Sacido
Extracellular vesicles (EVs) are small membrane-bound vesicles which play an important role in cell-to-cell communication. Their molecular cargo analysis is presented as a new source for biomarker detection, and it might provide an alternative to traditional solid biopsies. However, the most effective approach for EV isolation is not yet well established. Here, we study the efficiency of the most common EV isolation methods-ultracentrifugation, Polyethlyene glycol and two commercial kits, Exoquick® and PureExo®. We isolated circulating EVs from the bloodstream of healthy donors, characterized the size and yield of EVs and analyzed their protein profiles and concentration. Moreover, we have used for the first time Digital-PCR to identify and detect specific gDNA sequences, which has several implications for diagnostic and monitoring many types of diseases. Our findings present Polyethylene glycol precipitation as the most feasible and less cost-consuming EV isolation technique.

1 November 2016 in Acta Biomaterialia
Verified
Journal Article
Closed access
LFLaura Fernández-García
Laura Fernández-García
NMNúria Marí-Buyé
Núria Marí-Buyé
JBJuan A. Barios
Juan A. Barios
RMRodrigo Madurga
Rodrigo Madurga
MEManuel Elices
Manuel Elices
DGDaniel Gonzalez-Nieto
Daniel Gonzalez-Nieto

20 January 2021 in Cells
Verified
Journal Article
Open access
PDF file
Tomás DurajTomás Duraj
Tomás Duraj
NGNoemi Garcia
Noemi Garcia
PCPepa Carrion-Navarro
Pepa Carrion-Navarro
RMRodrigo Madurga
Rodrigo Madurga
Ana Ortiz de MendivilAna Ortiz de Mendivil
Ana Ortiz de Mendivil
ÁAÁngel Ayuso-Sacido
Ángel Ayuso-Sacido
Glioblastoma (GBM) is the most aggressive primary brain tumor, with a median survival at diagnosis of 16–20 months. Metabolism represents a new attractive therapeutic target; however, due to high intratumoral heterogeneity, the application of metabolic drugs in GBM is challenging. We characterized the basal bioenergetic metabolism and antiproliferative potential of metformin (MF), dichloroacetate (DCA), sodium oxamate (SOD) and diazo-5-oxo-L-norleucine (DON) in three distinct glioma stem cells (GSCs) (GBM18, GBM27, GBM38), as well as U87MG. GBM27, a highly oxidative cell line, was the most resistant to all treatments, except DON. GBM18 and GBM38, Warburg-like GSCs, were sensitive to MF and DCA, respectively. Resistance to DON was not correlated with basal metabolic phenotypes. In combinatory experiments, radiomimetic bleomycin exhibited therapeutically relevant synergistic effects with MF, DCA and DON in GBM27 and DON in all other cell lines. MF and DCA shifted the metabolism of treated cells towards glycolysis or oxidation, respectively. DON consistently decreased total ATP production. Our study highlights the need for a better characterization of GBM from a metabolic perspective. Metabolic therapy should focus on both glycolytic and oxidative subpopulations of GSCs.

1 February 2022 in Cancer Letters
Verified
Journal Article
Open access
AMAna Hernández Martínez
Ana Hernández Martínez
RMRodrigo Madurga
Rodrigo Madurga
NGNoemi Garcia
Noemi Garcia
ÁAÁngel Ayuso-Sacido
Ángel Ayuso-Sacido
Glioblastoma (GBM) is the most invasive and deadliest brain cancer in adults. Its inherent heterogeneity has been designated as the main cause of treatment failure. Thus, a deeper understanding of the diversity that shapes GBM pathobiology is of utmost importance. Single-cell RNA sequencing (scRNA-seq) technologies have begun to uncover the hidden composition of complex tumor ecosystems. Herein, a semi-systematic search of reference literature databases provided all existing publications using scRNA-seq for the investigation of human GBM. We compared and discussed findings from these works to build a more robust and unified knowledge base. All aspects ranging from inter-patient heterogeneity to intra-tumoral organization, cancer stem cell diversity, clonal mosaicism, and the tumor microenvironment (TME) are comprehensively covered in this report. Tumor composition not only differs across patients but also involves a great extent of heterogeneity within itself. Spatial and cellular heterogeneity can reveal tumor evolution dynamics. In addition, the discovery of distinct cell phenotypes might lead to the development of targeted treatment approaches. In conclusion, scRNA-seq expands our knowledge of GBM heterogeneity and helps to unravel putative therapeutic targets.

12 January 2021 in International Journal of Epidemiology
Verified
Journal Article
Closed access
JAJOSE FELIPE VARONA ARCHE
JOSE FELIPE VARONA ARCHE
RMRodrigo Madurga
Rodrigo Madurga
FPFrancisco Peñalver
Francisco Peñalver
EAElena Abarca
Elena Abarca
CACristina Almirall
Cristina Almirall
JVJose María Castellano Vázquez
Jose María Castellano Vázquez
Background: Spain has one of the highest incidences of coronavirus disease 2019 (COVID-19) worldwide, so Spanish health care workers (HCW) are at high risk of exposure. Our objective was to determine severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody seroprevalence amongst HCW and factors associated with seropositivity. Methods: A cross-sectional study evaluating 6190 workers (97.8% of the total workforce of a healthcare-system of 17 hospitals across four regions in Spain) was carried out between April and June 2020, by measuring immunoglobulin G (IgG)-SARS-CoV-2 antibody titres and related clinical data. Exposure risk was categorized as high (clinical environment; prolonged/direct contact with patients), moderate (clinical environment; non-intense/no patient contact) and low (non-clinical environment). Results: A total of 6038 employees (mean age 43.8 years; 71% female) were included in the final analysis. A total of 662 (11.0%) were seropositive for IgG against SARS-CoV-2 (39.4% asymptomatic). Adding available PCR-testing, 713 (11.8%) employees showed evidence of previous SARS-CoV-2 infection. However, before antibody testing, 482 of them (67%) had no previous diagnosis of SARS-CoV-2-infection. Seroprevalence was higher in high- and moderate-risk exposure (12.1 and 11.4%, respectively) compared with low-grade risk subjects (7.2%), and in Madrid (13.8%) compared with Barcelona (7.6%) and Coruña (2.0%). High-risk [odds ratio (OR): 2.06; 95% confidence interval (CI): 1.63–2.62] and moderate-risk (OR: 1.77; 95% CI: 1.32–2.37) exposures were associated with positive IgG-SARS-CoV-2 antibodies after adjusting for region, age and sex. Higher antibody titres were observed in moderate–severe disease (median antibody-titre: 13.7 AU/mL) compared with mild (6.4 AU/mL) and asymptomatic (5.1 AU/mL) infection, and also in older (>60 years: 11.8 AU/mL) compared with younger (<30 years: 4.2 AU/mL) people. Conclusions: Seroprevalence of IgG-SARS-CoV-2 antibodies in HCW is a little higher than in the general population and varies depending on regional COVID-19 incidence. The high rates of subclinical and previously undiagnosed infection observed in this study reinforce the utility of antibody screening. An occupational risk for SARS-CoV-2 infection related to working in a clinical environment was demonstrated in this HCW cohort.